Biocon Biologics secures multiple market access agreements in US for Yesintek Ruchika Sharma5 May 2025 12:50 PM ISTYESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
Biocon Biologics receives EMA Committee positive opinions for Biosimilar Denosumab for bone health Written By Ruchika Sharma26 April 2025 12:36 PM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the Committee...
Priyadarshini Mahapatra to exit Syngene International as Head Legal, Company Secretary & Compliance Officer Ruchika Sharma24 April 2025 2:46 PM ISTKarnataka: Syngene International Limited, a listed subsidiary of Biocon Limited, has announced the resignation of Priyadarshini...
Biocon Biologics secures market entry date for ophthalmology drug Yesafili in US Written By Ruchika Sharma15 April 2025 4:18 PM ISTAdditionally, Biocon Biologics secured a settlement agreement in Canada with Bayer and Regeneron Pharma for launch of YESAFILI no later than July 1,...
"Who's going to pay price to bring back manufacturing in US", asks Biocon MD Ruchika Sharma15 April 2025 10:30 AM ISTNew Delhi: Siddharth Mittal, the CEO and Managing Director of Biocon Limited, raised a critical question on Friday, asking who would bear...
Biocon arm secures USFDA approval for Everolimus Tablets for prophylaxis of organ rejection in adult patients Written By Ruchika Sharma11 April 2025 12:30 PM ISTBangalore: Biocon Limited has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval...
Biocon Biologics gets USFDA nod for cancer drug Jobevne Written By Ruchika Sharma10 April 2025 12:39 PM ISTBengaluru: Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced that the U.S. Food and Drug Administration (U.S. FDA) has...
Biocon to raise up to Rs 600 crore Ruchika Sharma7 April 2025 4:15 PM ISTBangalore: In a recent BSE filing, Biocon has said that its Board of Directors has approved to raise up to Rs 600 crore in one or...
Biocon Pharma gets USFDA approval for BP-raising injection in adults with acute hypotension Written By Ruchika Sharma24 March 2025 11:30 AM ISTBengaluru: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval from the...
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics Written By Ruchika Sharma8 March 2025 1:30 PM ISTBengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced the successful results...
Biocon Biologics, Civica join hands to expand Insulin Aspart access in US Written By Ruchika Sharma7 March 2025 11:30 AM ISTCivica will commercialize the medicine for patients in the United States, after completion of development work and clinical trials.
Biocon arm gets USFDA nod for cancer, deep vein thrombosis drugs Written By Ruchika Sharma5 March 2025 11:30 AM ISTBangalore: Biocon Limited has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received final approvals...
